All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Impact of induction regimen and allo-HSCT on survival outcomes in patients with Ph+ ALL
|
A multi-institutional, real-world, retrospective analysis conducted through the COMMAND assessed the outcomes of patients with Ph+ ALL.1 This analysis included 431 adult patients diagnosed between May 2003 and December 2022, who received treatment with either IC (n = 317) or NIC (n = 112) first-line TKI-based regimens, with or without allo-HSCT.1 Results from this analysis were published in the American Journal of Hematology by Badar, et al.1 |
| Key learnings |
|
The study demonstrated that, in comparison to first-generation TKIs, second- and third-generation TKIs improved RFS and OS in patients with Ph+ ALL. The 3-year RFS rates with second- and third-generation TKIs were 66% compared to 47.5% with first-generation TKIs (HR, 0.76; p = 0.087), while the 3-year OS rates were 71.1% vs 55.7%, respectively (HR, 0.66; p = 0.026). |
|
IC + TKI regimens were associated with improved long-term survival outcomes than NIC + TKI; median RFS was 129 months vs 36.93 months for IC + TKI and NIC + TKI, respectively (p = 0.003), and median OS was 123.1 months vs 49.40 months, respectively (p = 0.01). |
|
In the multivariable analysis, allo-HSCT improved RFS vs no allo-HSCT, regardless of whether patients achieved CMR at 3 months (HR, 0.32; p < 0.001) or did not achieve CMR (HR, 0.22; p <0.001). This benefit remained significant after a baseline time point of 180 days following diagnosis (HR, 0.39; p < 0.001) and 180 days post-allo-HSCT in a propensity-score-matched cohort (HR, 0.37; p < 0.001). |
|
Allo-HSCT did not improve OS based on achieving CMR at 3 months (HR, 0.87; p = 0.59) or not achieving CMR (HR, 0.48; p = 0.11). |
|
Similarly, OS showed no improvement when assessed after a baseline timepoint of 180 days following diagnosis (HR, 0.75; p = 0.09) and post 180 days of allo-HSCT in a propensity-score-matched cohort (HR, 0.57; p = 0.06); however, in the multivariable analysis using propensity match score, allo-HSCT improved OS (HR, 0.53; p = 0.04). |
|
The findings suggest that treatment strategies incorporating newer-generation TKIs and judicious use of allo-HSCT may improve outcomes in patients with Ph+ ALL; however, further studies are needed to refine the selection criteria for allo-HSCT candidates. |
Abbreviations: ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; CMR, complete molecular remission; COMMAND, Consortium on Myeloid Malignancies and Neoplastic Diseases; HR, hazard ratio; IC, intensive chemotherapy; NIC, non-intensive chemotherapy; OS, overall survival; Ph+, Philadelphia-positive; RFS, relapse-free survival; TKI, tyrosine kinase inhibitor.
- Badar T, Narra R, Mims AS, et al. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024. Online ahead of print. DOI: 10.1002/ajh.27475
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox